RESUMO
HFE, the protein that is mutated in hereditary haemochromatosis, binds to the transferrin receptor (TfR). Here we show that wild-type HFE and TfR localize in endosomes and at the basolateral membrane of a polarized duodenal epithelial cell line, whereas the primary haemochromatosis HFE mutant, and another mutant with impaired TfR-binding ability accumulate in the ER/Golgi and at the basolateral membrane, respectively. Levels of the iron-storage protein ferritin are greatly reduced and those of TfR are slightly increased in cells expressing wild-type HFE, but not in cells expressing either mutant. Addition of an endosomal-targeting sequence derived from the human low-density lipoprotein receptor (LDLR) to the TfR-binding-impaired mutant restores its endosomal localization but not ferritin reduction or TfR elevation. Thus, binding to TfR is required for transport of HFE to endosomes and regulation of intracellular iron homeostasis, but not for basolateral surface expression of HFE.
Assuntos
Antígenos HLA/metabolismo , Antígenos de Histocompatibilidade Classe I/metabolismo , Ferro/metabolismo , Proteínas de Membrana , Receptores da Transferrina/metabolismo , Transporte Biológico Ativo , Linhagem Celular , Polaridade Celular , Endocitose , Endossomos/metabolismo , Células Epiteliais/metabolismo , Proteínas de Fluorescência Verde , Antígenos HLA/genética , Hemocromatose/genética , Hemocromatose/imunologia , Hemocromatose/metabolismo , Proteína da Hemocromatose , Antígenos de Histocompatibilidade Classe I/genética , Homeostase , Humanos , Proteínas Luminescentes/genética , Proteínas Luminescentes/metabolismo , Microscopia Confocal , Modelos Biológicos , Mutação , Ligação Proteica , Receptores de LDL/genética , Receptores de LDL/metabolismo , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/metabolismo , TransfecçãoRESUMO
The use of nanovectors in several medicinal treatments has reached a great importance in the last decade. Some drugs need to be protected to increase their lifetimes in the blood flow, to avoid degradation, to be delivered into target cells or to decrease their side effects. The goal of this work was to design and prepare nanovectors formed by novel surfactants derived from the [Ru(bpy)3]2+ complex. These amphiphilic molecules are assembled to form metallomicelles which can act as pharmaceutical agents and, at the same time, as nanovectors for several drugs. TEM images showed a structural transition from spherical to elongated micelles when the surfactant concentration increased. Fluorescence microscopy confirmed the internalization of these metallomicelles into diverse cell lines and cytotoxicity assays demonstrated specificity for some human cancer cells. The encapsulation of various antibiotics was carried out as well as a thorough study about the DNA condensation by the metallomicelles. To the best of our knowledge, applications of these metallomicelles have not been shown in the literature yet.
Assuntos
Complexos de Coordenação/química , Micelas , Nanopartículas/química , Rutênio/química , Células A549 , Linhagem Celular , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Complexos de Coordenação/farmacologia , Composição de Medicamentos , Células Hep G2 , Humanos , Células MCF-7 , Microscopia de Força Atômica , Microscopia Confocal , Microscopia Eletrônica de Transmissão , Nanopartículas/ultraestrutura , Rutênio/farmacologiaRESUMO
Although there is a WHO guidance for a limit on residual DNA for parenterally administered vaccines produced on continuous cell lines, there is no corresponding guidance for oral vaccines. To help determine an oral limit, we performed a study of Vero cell DNA uptake in rats, in which the relative uptake and persistence of Vero cell DNA administered orally was compared to its uptake when delivered intramuscularly (IM). The results of this study allowed the generation of an empirically derived IM versus oral factor (10(6)) representing the relative inefficiency of DNA uptake by oral administration. This factor was then applied to the WHO recommended parenteral limit of 10 ng/dose to determine a corresponding upper limit on the level of residual Vero cell DNA for an oral vaccine of 10 mg. As a conservative approach, this empirically determined limit was reduced 100-fold to 100 microg. Thus, the results of this animal study, together with additional evidence in the literature, support a residual DNA safety limit of 100 microg per dose for an oral vaccine produced on a continuous cell line.
Assuntos
DNA/administração & dosagem , DNA/efeitos adversos , Vacinas/normas , Administração Oral , Animais , Linhagem Celular , Chlorocebus aethiops , DNA/farmacocinética , Desoxirribonucleases , Endocitose , Endossomos/fisiologia , Feminino , Humanos , Masculino , Guias de Prática Clínica como Assunto , Vacinas/administração & dosagem , Células Vero , Organização Mundial da SaúdeRESUMO
HFE is a class I major histocompatibility complex (MHC)-related protein that is mutated in patients with the iron storage disease hereditary hemochromatosis. HFE binds tightly to transferrin receptor (TfR), the receptor that mediates uptake of iron-loaded transferrin. The binding affinities for TfR of HFE mutants, designed using the HFE crystal structure, were measured using biosensor assays. The results allow localization of the TfR binding site on HFE to the C-terminal portion of the alpha1 domain helix and an adjacent loop, a region distinct from the ligand binding sites on class I MHC and related proteins. A biosensor-derived pH-dependent affinity profile for the HFE-TfR interaction is discussed in terms of HFE's hypothesized role in intracellular trafficking.
Assuntos
Antígenos HLA/metabolismo , Hemocromatose/metabolismo , Antígenos de Histocompatibilidade Classe I/metabolismo , Proteínas de Membrana , Receptores da Transferrina/metabolismo , Animais , Sítios de Ligação , Células CHO , Cricetinae , Antígenos HLA/química , Antígenos HLA/genética , Hemocromatose/genética , Proteína da Hemocromatose , Antígenos de Histocompatibilidade Classe I/química , Antígenos de Histocompatibilidade Classe I/genética , Humanos , Concentração de Íons de Hidrogênio , Ligantes , Mutagênese Sítio-Dirigida , Conformação ProteicaRESUMO
HFE is a class I major histocompatibility complex (MHC)-related protein that is mutated in patients with the iron overload disease hereditary hemochromatosis. HFE binds to transferrin receptor (TfR), the receptor used by cells to obtain iron in the form of diferric transferrin (Fe-Tf). Previous studies demonstrated that HFE and Fe-Tf can bind simultaneously to TfR to form a ternary complex, and that membrane-bound or soluble HFE binding to cell surface TfR results in a reduction in the affinity of TfR for Fe-Tf. We studied the inhibition by soluble HFE of the interaction between soluble TfR and Fe-Tf using radioactivity-based and biosensor-based assays. The results demonstrate that HFE inhibits the TfR:Fe-Tf interaction by binding at or near the Fe-Tf binding site on TfR, and that the Fe-Tf:TfR:HFE ternary complex consists of one Fe-Tf and one HFE bound to a TfR homodimer.
Assuntos
Compostos Férricos/metabolismo , Antígenos HLA/metabolismo , Antígenos de Histocompatibilidade Classe I/metabolismo , Proteínas de Membrana , Receptores da Transferrina/metabolismo , Transferrina/metabolismo , Ligação Competitiva , Técnicas Biossensoriais , Antígenos HLA/genética , Hemocromatose/metabolismo , Proteína da Hemocromatose , Antígenos de Histocompatibilidade Classe I/genética , Humanos , Ligação Proteica , Proteínas Recombinantes/metabolismoRESUMO
A study of a dinitro-diester calix[4]arene (5,17-(3-nitrobenzylideneamino)-11,23-di-tert-butyl-25,27-diethoxycarbonyl methyleneoxy-26,28-dihydroxycalix[4]arene) interaction with calf-thymus DNA was carried out using several techniques. The measurements were done at various molar ratios X=[calixarene]/[DNA]. Results show diverse changes in the DNA conformation depending on the X value. Thus, at low macrocycle concentrations, the calixarene binds to the polynucleotide. This interaction, mainly in groove mode, weakens the hydrogen bonds between base pairs of the helix inducing denaturation of the double strands, as well as condensation of the macromolecule, from an extended coil state to a globular state. An opposite effect is observed at X molar ratios higher than 0.07. The de-condensation of DNA happens, that is, the transition from a compact state to a more extended conformation, probably due to the stacking of calixarene molecules in the solution. Results also show the importance of making a proper choice of the system under consideration.
Assuntos
Calixarenos/metabolismo , DNA/metabolismo , Desnaturação de Ácido Nucleico , Animais , Bovinos , Dicroísmo Circular , Etídio/química , Microscopia de Força Atômica , Espectrometria de Fluorescência , ViscosidadeRESUMO
With the idea of improving and advancing the design and preparation of new reagents based on cationic surfactants for gene therapy, two luminescent metallosurfactants derived from the [Ru(2,2'-bpy)3](2+) complex were synthesized. Their interaction with DNA and the effect they exert on the conformation of the polynucleotide were studied by using different techniques. The equilibrium binding constants, Kb, of the two surfactants to DNA were obtained at different molar ratios X=[surfactant]/[DNA]. The observed sigmoidal dependence of Kb on X confirms the cooperative character of the binding. After the addition of a determined surfactant concentration, the condensation of the polymer was observed. The amount of surfactant needed to produce this conformational change is lower for the double stranded surfactant than for the single chain surfactant due to a stronger hydrophobic interaction. The addition of α-cyclodextrin molecules to the metallosurfactant/DNA solutions results in polynucleotide decompaction, which confirms the importance of the hydrophobic interactions in the condensation of the polynucleotide. Results also show the importance of choosing both a proper system to study and the most seeming measuring technique to use. It is demonstrated that, in some cases, the use of several techniques is desirable to obtain reliable and accurate results.
Assuntos
DNA/química , Metais/química , Rubídio/química , Tensoativos/química , Espectrometria de FluorescênciaRESUMO
Recognition of self peptides bound to the class I major histocompatibility complex molecule HLA-B27 is thought to trigger proliferation of autoreactive T cells and result in autoimmune arthritic diseases. Previous work from other laboratories established that a predominant feature of endogenous peptides eluted from purified B27 is an arginine at position 2. We studied the binding of peptides containing both natural and unnatural amino acids by the subtype HLA-B*2702, with the goal of gaining insight into peptide binding by this B27 subtype that is associated with susceptibility to arthritic disease. A soluble from of B*2702 was depleted of endogenous peptides. We tested the binding of peptides substituted with cysteine, homocysteine, or an alpha-amino-epsilon-mercapto hexanoic acid side chain (Amh) instead of the naturally occurring arginine at position 2, to determine whether the peptide sulfhydryl residue could be covalently linked to cysteine 67 in the B*2702 binding cleft. Although none of the altered peptide sequences bound covalently to B*2702, the affinities of the homocysteine- and Amh-substituted peptides were close to that of the native peptide sequence. Substitutions at position 2 with other side chains, such as glutamine and methionine, also resulted in peptides that bound with only slightly reduced affinity. These results demonstrate that peptide side chains other than arginine at position 2 can be accomodated within the B*2702 peptide binding site with only minor reductions in affinity. This extended repertoire of permissible B27-binding peptides should be taken into account for a consideration of disease-associated peptide sequences.
Assuntos
Antígeno HLA-B27/metabolismo , Biblioteca de Peptídeos , Peptídeos/metabolismo , Animais , Apresentação de Antígeno , Arginina/química , Artrite/imunologia , Autoantígenos/química , Autoantígenos/imunologia , Doenças Autoimunes/imunologia , Células CHO , Cricetinae , Cricetulus , Humanos , Ligantes , Peptídeos/síntese química , Peptídeos/química , Conformação Proteica , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes de Fusão/metabolismoRESUMO
Generating monoclonal antibodies (mAbs) against one polypeptide chain of a heterodimeric protein can be difficult when the other chain is more immunogenic. To influence the immune response in favor of the less immunogenic protein, we rendered adult mice tolerant to the immunodominant protein using a procedure based on the phenomenon of high zone tolerance. We then immunized the tolerized mice with a heterodimeric protein containing the immunogenic protein and produced hybridomas in the usual way. Screening the hybridomas for reactivity against the immunodominant protein and against the heterodimer revealed that this tolerization procedure can result in an increase of hybridomas producing mAbs against the protein of interest by up to 90-fold. This method should be of general utility for the production of mAbs against weakly antigenic proteins in mixtures of antigens.
Assuntos
Anticorpos Monoclonais/biossíntese , Tolerância Imunológica , Epitopos Imunodominantes/imunologia , Epitopos Imunodominantes/farmacologia , Lectinas Tipo C , Proteínas de Membrana , Animais , Anticorpos Monoclonais/imunologia , Antígenos CD/imunologia , Antígenos CD/farmacologia , Células CHO/metabolismo , Cricetinae , Dimerização , Feminino , Antígenos HLA/imunologia , Antígenos HLA/metabolismo , Antígenos HLA/farmacologia , Proteína da Hemocromatose , Antígenos de Histocompatibilidade Classe I/imunologia , Antígenos de Histocompatibilidade Classe I/metabolismo , Antígenos de Histocompatibilidade Classe I/farmacologia , Hibridomas , Glicoproteínas de Membrana/imunologia , Glicoproteínas de Membrana/farmacologia , Camundongos , Camundongos Endogâmicos BALB C , Subfamília D de Receptores Semelhantes a Lectina de Células NK , Microglobulina beta-2/imunologiaRESUMO
Preclinical studies suggest that in addition to the well-known direct damage to the myocardium, anthracycline antineoplastic drugs exert toxic effects on the cardiovascular autonomic system as well. To investigate whether this phenomenon occurs in the clinic, we carried out noninvasive, widely used tests of cardiovascular autonomic physiology in 55 women with stage II or III breast cancer. In all, 31 were being treated with anthracycline-containing chemotherapy regimens, and 24 who were receiving CMF (cyclophosphamide, Methotrexate, and fluorouracil) served as controls. Of 279 tests conducted in anthracycline (A)-treated patients, 123 were abnormal, vs 54 of 216 tests carried out in 24 controls (44% vs 25%; P less than 0.005). Abnormal variations in heart rate on standing and in diastolic blood pressure during handgrip was found in 25 (81%) and 17 patients receiving A, vs 9 (37%; P less than 0.005) and 5 (21%; P less than 0.0001), respectively, in controls. The incidence of abnormal tests was significantly higher in A-treated patients greater than 60 years of age (41%) vs 67%; P less than 0.05). Radionuclide ventriculography was carried out in 19 patients who showed abnormal tests of cardiovascular autonomic function after greater than or equal to 6 courses of a-containing chemotherapy; only 1 of them had abnormal cardiac contractility (global hypokinesia), suggesting that abnormal tests of cardiovascular autonomic function may occur in the absence of a detectable deterioration in left ventricular ejection fraction. A large number of factors may alter cardiovascular autonomic function in cancer patients, including age, radiation therapy to the chest, and multidrug treatment. Even after correcting for the most obvious of these, chemotherapy with anthracyclines is associated with a significantly higher percentage of abnormal tests for cardiovascular autonomic function. Although indirect and semi-quantitative, our results are compatible with the idea of A-induced cardiac autonomic dysfunction.
Assuntos
Antibióticos Antineoplásicos/efeitos adversos , Sistema Nervoso Autônomo/efeitos dos fármacos , Neoplasias da Mama/fisiopatologia , Sistema Cardiovascular/efeitos dos fármacos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Sistema Nervoso Autônomo/fisiopatologia , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Neoplasias da Mama/tratamento farmacológico , Sistema Cardiovascular/fisiopatologia , Cisplatino/administração & dosagem , Avaliação de Medicamentos , Eletrocardiografia , Feminino , Fluoruracila/administração & dosagem , Humanos , Metotrexato/administração & dosagem , Respiração/efeitos dos fármacos , Respiração/fisiologia , Volume Sistólico/efeitos dos fármacos , Volume Sistólico/fisiologia , Manobra de ValsalvaRESUMO
AIDS: Jesus Lebron, a gay political activist and person living with AIDS, had a battle with the New York City Civilian Complaint Review Board (CCRB). The agency was created to monitor allegations of police brutality and discrimination against minority groups. It is made up of Asian-Americans, Latins, and gay and lesbian activists. Beginning in the winter of 1993-94, Rev. Ruben Diaz, a member of the CCRB, expressed publicly his AIDS-phobic philosophy. The Gay and Lesbian American (GLA) group sent protest letters to the CCRB demanding that Rev. Diaz be removed. No responses were received. Christopher Lynn, a board member and a gay HIV-positive lawyer, was present at the CCRB open meeting on Oct. 5, 1994. Voices and tempers were flaring and Jesus Lebron, losing control of his temper, flung a jug of water at Diaz and soaked Mr. Lynn as well. Lynn filed both civil and criminal charges, which were later dropped. The interview with Mr. Lebron elaborates on the opinions, feelings and facts which led to and followed the incident.^ieng
Assuntos
Síndrome da Imunodeficiência Adquirida , Homossexualidade , Manobras Políticas , Grupos Minoritários , Cidade de Nova Iorque , PreconceitoRESUMO
Two new surfactants derived from the tris(2,2'-bipyridine) ruthenium(II) complex, [Ru(2,2'-bpy)(3)](2+), were synthesized and characterized: the double-tailed [Ru(2,2'-bipy)2(4,4'-(C(11)H(23))(2)-2,2'-bipy)](2+) surfactant (RuC11) and the mono-tailed [Ru(2,2'-bipy)(2)(4-(CH(3))-4'-(C(13)H(27))-2,2'-bipy)](2+) surfactant (RuC13). The main characteristic of these species is the presence of an inorganic complex as the polar head of the surfactant with interesting luminescence properties, which were used to study the interaction of these cationic surfactants with α-, ß- and γ-cyclodextrins (CD). The results showed the formation of [2]- and [3]-pseudorotaxanes. The binding constant values as well as the stoichiometry of the complexes formed were obtained; the results were confirmed, from a qualitative point of view, with NMR spectra.
RESUMO
HFE is related to major histocompatibility complex (MHC) class I proteins and is mutated in the iron-overload disease hereditary haemochromatosis. HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin. The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer. On a cell membrane containing both proteins, HFE would 'lie down' parallel to the membrane, such that the HFE helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the TfR dimerization domain. The structures of TfR alone and complexed with HFE differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between TfR chains. The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.
Assuntos
Antígenos HLA/química , Hemocromatose , Antígenos de Histocompatibilidade Classe I/química , Proteínas de Membrana , Receptores da Transferrina/química , Cristalografia por Raios X , Antígenos HLA/genética , Antígenos HLA/metabolismo , Hemocromatose/genética , Proteína da Hemocromatose , Antígenos de Histocompatibilidade Classe I/genética , Antígenos de Histocompatibilidade Classe I/metabolismo , Humanos , Concentração de Íons de Hidrogênio , Ferro/metabolismo , Substâncias Macromoleculares , Modelos Moleculares , Mutação , Ligação Proteica , Conformação Proteica , Receptores da Transferrina/metabolismo , Transferrina/metabolismoRESUMO
We have previously reported that a beta-endorphin-like substance inhibits phagocytosis in Tetrahymena perhaps by a mu-like opioid receptor. We now report a further characterization of the elements involved in the signal transduction mechanism of this opioid. Affinity chromatography followed by immunoblots of both intracellular extracts and extracellular medium reveal the presence of two main proteins of 64 and 75 kDa. These molecular weights are much higher than that of any known opioid peptide or precursor protein and suggest that we may be dealing with either a novel opioid or with proteins that by chance cross-react with anti-beta-endorphin antibody. Nevertheless, when the biological activity of these proteins was tested it was found that they had an effect similar to that of mammalian beta-endorphin, namely inhibition of phagocytosis by a naloxone-reversible mechanism. We have probed a size-selected Tetrahymena library with a pro-opiomelanocortin probe and have obtained several positive clones; the sequencing of their inserts should establish whether we are dealing with a bona fide member of the opioid family. Another aspect we have been studying is the G-proteins which appear to be involved in the modulation of phagocytosis. We have found, by means of Western blotting (using an antibody against the conserved GTP-binding region of the alpha-subunit), two bands of 51 and 59 kDa; no alpha-subunit of 59 kDa had been reported previously and may represent a novel G-protein. In spite of these differences, the opioid signal transduction mechanism appears to remarkably resemble that present in more complex organisms.
Assuntos
Fagocitose , Tetrahymena/fisiologia , beta-Endorfina/fisiologia , Animais , Southern Blotting , Reações Cruzadas , DNA Fúngico/análise , Immunoblotting , Mamíferos , Naloxona/farmacologia , Fagocitose/efeitos dos fármacos , Pró-Opiomelanocortina/biossíntese , Ratos , Receptores Opioides/fisiologia , beta-Endorfina/isolamento & purificação , beta-Endorfina/farmacologiaRESUMO
HFE is an MHC-related protein that is mutated in the iron-overload disease hereditary hemochromatosis. HFE binds to transferrin receptor (TfR) and reduces its affinity for iron-loaded transferrin, implicating HFE in iron metabolism. The 2.6 A crystal structure of HFE reveals the locations of hemochromatosis mutations and a patch of histidines that could be involved in pH-dependent interactions. We also demonstrate that soluble TfR and HFE bind tightly at the basic pH of the cell surface, but not at the acidic pH of intracellular vesicles. TfR:HFE stoichiometry (2:1) differs from TfR:transferrin stoichiometry (2:2), implying a different mode of binding for HFE and transferrin to TfR, consistent with our demonstration that HFE, transferrin, and TfR form a ternary complex.
Assuntos
Antígenos HLA/química , Antígenos HLA/metabolismo , Antígenos de Histocompatibilidade Classe I/química , Antígenos de Histocompatibilidade Classe I/metabolismo , Proteínas de Membrana , Estrutura Secundária de Proteína , Receptores da Transferrina/metabolismo , Sequência de Aminoácidos , Sítios de Ligação , Membrana Celular/metabolismo , Cristalografia por Raios X/métodos , Antígenos HLA/genética , Hemocromatose/genética , Proteína da Hemocromatose , Antígenos de Histocompatibilidade Classe I/genética , Humanos , Concentração de Íons de Hidrogênio , Cinética , Modelos Moleculares , Receptores da Transferrina/químicaRESUMO
A 45-kDa membrane polypeptide that is associated with activity of the particulate methane monooxygenase (pMMO) has been purified from three methanotrophic bacteria, and the N-terminal amino acid sequence was found to be identical in 17 of 20 positions for all three polypeptides and identical in 14 of 20 positions for the N terminus of AmoB, the 43-kDa subunit of ammonia monooxygenase. DNA from a variety of methanotrophs was screened with two probes, an oligonucleotide designed from the N-terminal sequence of the 45-kDa polypeptide from Methylococcus capsulatus Bath and an internal fragment of amoA, which encodes the 27-kDa subunit of ammonia monooxygenase. In most cases, two hybridizing fragments were identified with each probe. Three overlapping DNA fragments containing one of the copies of the gene encoding the 45-kDa pMMO polypeptide (pmoB) were cloned from Methylococcus capsulatus Bath. A 2.1-kb region was sequenced and found to contain both pmoB and a second gene, pmoA. The predicted amino acid sequences of these genes revealed high identity with those of the gene products of amoB and amoA, respectively. Further hybridization experiments with DNA from Methylococcus capsulatus Bath and Methylobacter albus BG8 confirmed the presence of two copies of pmoB in both strains. These results suggest that the 45- and 27-kDa pMMO-associated polypeptides of methanotrophs are subunits of the pMMO and are present in duplicate gene copies in methanotrophs.
Assuntos
Genes Bacterianos , Methylococcaceae/genética , Oxigenases/genética , Sequência de Aminoácidos , Sequência de Bases , Clonagem Molecular , Proteínas de Membrana/genética , Metano/metabolismo , Methylococcaceae/enzimologia , Dados de Sequência Molecular , Hibridização de Ácido Nucleico , Mapeamento por Restrição , Alinhamento de Sequência , Homologia de Sequência de Aminoácidos , SolubilidadeRESUMO
We recently reported the positional cloning of a candidate gene for hereditary hemochromatosis called HFE. The gene product, a member of the major histocompatibility complex class I-like family, was found to have a mutation, Cys-282 --> Tyr (C282Y), in 85% of patient chromosomes. This mutation eliminates the ability of HFE to associate with beta2-microglobulin (beta2m) and prevents cell-surface expression. A second mutation that has no effect on beta2m association, H63D, was found in eight out of nine patients heterozygous for the C282Y mutant. In this report, we demonstrate in cultured 293 cells overexpressing wild-type or mutant HFE proteins that both the wild-type and H63D HFE proteins form stable complexes with the transferrin receptor (TfR). The C282Y mutation nearly completely prevents the association of the mutant HFE protein with the TfR. Studies on cell-associated transferrin at 37 degrees C suggest that the overexpressed wild-type HFE protein decreases the affinity of the TfR for transferrin. The overexpressed H63D protein does not have this effect, providing the first direct evidence for a functional consequence of the H63D mutation. Addition of soluble wild-type HFE/beta2m heterodimers to cultured cells also decreased the apparent affinity of the TfR for its ligand under steady-state conditions, both in 293 cells and in HeLa cells. Furthermore, at 4 degrees C, the added soluble complex of HFE/beta2m inhibited binding of transferrin to HeLa cell TfR in a concentration-dependent manner. Scatchard plots of these data indicate that the added heterodimer substantially reduced the affinity of TfR for transferrin. These results establish a molecular link between HFE and a key protein involved in iron transport, the TfR, and raise the possibility that alterations in this regulatory mechanism may play a role in the pathogenesis of hereditary hemochromatosis.
Assuntos
Antígenos HLA/genética , Hemocromatose/genética , Antígenos de Histocompatibilidade Classe I/genética , Proteínas de Membrana , Receptores da Transferrina/metabolismo , Sequência de Aminoácidos , Dimerização , Proteína da Hemocromatose , Humanos , Ligantes , Mutação Puntual , Testes de Precipitina , Ligação Proteica , Relação Estrutura-Atividade , Transfecção , Transferrina/metabolismo , Microglobulina beta-2/metabolismoRESUMO
Desde 1985 hemos tratado 99 pacientes con cáncer de mama estadio III (operables e inoperables) con una misma estrategía, combinando QT primaria, radioterapia, cirugía y QT de consolidación. Hubo 75 estadios IIIB y 24 estadios IIIA. En 11 casos se pudo realizar cirugía conservadora. Tuvimos 6 respuestas patológicas completas. Cuarenta y ocho pacientes han cumplido 2 años de tratadas y se consideraron evaluables. La mediana de SV fue d3e 60-66 meses. El porcentaje de SV en este grupo es 45,8 por ciento. Se analiza la incidencia de los distintos factores pronóstico en la SV. No se observó recidiva local en los casos en que se conservó la mama. Tuvimos muy baja toxicidad y se concluye con la necesidad de buscar tratamientos sistémicos más agresivos que podrían incidir en un futuro incremento de SV
Assuntos
Humanos , Feminino , Adulto , Pessoa de Meia-Idade , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/radioterapia , Neoplasias da Mama/cirurgia , Mastectomia , Estadiamento de Neoplasias , Biópsia , MamografiaRESUMO
Desde 1985 hemos tratado 99 pacientes con cáncer de mama estadio III (operables e inoperables) con una misma estrategía, combinando QT primaria, radioterapia, cirugía y QT de consolidación. Hubo 75 estadios IIIB y 24 estadios IIIA. En 11 casos se pudo realizar cirugía conservadora. Tuvimos 6 respuestas patológicas completas. Cuarenta y ocho pacientes han cumplido 2 años de tratadas y se consideraron evaluables. La mediana de SV fue d3e 60-66 meses. El porcentaje de SV en este grupo es 45,8 por ciento. Se analiza la incidencia de los distintos factores pronóstico en la SV. No se observó recidiva local en los casos en que se conservó la mama. Tuvimos muy baja toxicidad y se concluye con la necesidad de buscar tratamientos sistémicos más agresivos que podrían incidir en un futuro incremento de SV